Cardiology Rx (Repurposed)

Colchicine

Grade and summary pending review Evidence Grade Strength of published clinical evidence — not a safety rating or a recommendation. How to read this

Dimension Scores

Human Outcome

•

Biomarker Relevance

•

Signal Source Quality

•

Organ Specificity

•

Interaction Certainty

•

Translational Maturity

•

Per-dimension evidence strength is part of the full analysis Unlock full analysis

No indication-level signals recorded yet. The grade above has not been decomposed, so it should be read as a whole-compound assessment rather than a claim about any one indication.

Evidence Summary

An anti-inflammatory drug with two large trials showing it lowers the risk of heart attacks and strokes in people who already have cardiovascular disease. FDA-approved in 2023 for that use. Important nuance: it reduces cardiovascular events but did NOT improve overall survival, and the newest trial is less clear-cut. It is a cardiovascular medication, not a longevity supplement.

Safety Considerations

Benefit is on cardiovascular events, not overall lifespan (all-cause mortality neutral; a signal toward more non-cardiovascular deaths). GI side effects; narrow dosing considerations. Prescription drug — use only under medical supervision. Off-label 'anti-inflammaging' longevity use is not supported by the evidence.

Evidence Signals (0)

🔒

Create a free account to see signal-level evidence grades.

Create a free account

Products Containing Colchicine

No commercial products are currently listed for this molecule.

This evidence profile reflects publicly available research as of October 22, 2026. Evidence grades may change as new research is published. ClinEvident grades the quality of published evidence — it does not evaluate the efficacy of any specific commercial product.